Jaguar health enters exclusive crofelemer license and commercialization agreement with synworld technologies for canalevia for treatment of diarrhea in dogs in china

License fees of $5.0 million, and up to $5.0 million in unregistered equity infusion, over next 24 months service agreement of up to $5.0 million payable in unregistered jaguar stock to synworld to support approval of crofelemer in china, providing jaguar health with up to 80% of profits san francisco, ca / accesswire / june 29, 2022 / jaguar health, inc. (nasdaq:jagx) (jaguar) today announced that the company has entered an exclusive license and services agreement with ontario, canada-based synworld technologies corporation (synworld) for the treatment of diarrhea in dogs in the china market with jaguar's canalevia® (crofelemer delayed-release tablets) prescription drug product. "we are very excited about the possibility of making canalevia available in china as part of the license we have provided to synworld for crofelemer for treatment of diarrhea in dogs in this territory," said lisa conte, jaguar's founder, president, and ceo.
JAGX Ratings Summary
JAGX Quant Ranking